1374524-68-1
Chemical Structure
ME-344
- CAS No.: 1374524-68-1
- Formula:C22H20O4
- Molecular Weight:348.39
IUPAC Name: 4,4'-((3R,4S)-7-hydroxy-8-methylchromane-3,4-diyl)diphenol
InChIKey: QVCAATSEPLQVBX-FPOVZHCZSA-N
SMILES: OC1=CC=C2[C@H](C3=CC=C(O)C=C3)[C@H](C4=CC=C(O)C=C4)COC2=C1C
Biological Activity: ME-344 is an Isoflavone. ME-344 increases mitochondrial ROS generation. ME-344 inhibits tubulin polymerization. ME-344 inhibits HO-1 and impacts its mitochondrial translocation. ME-344 induces Apoptosis through Caspase 3 activation. ME-344 synergizes with Vinblastine in leukemia cells. ME-344 displays anti-tumor activity against leukemia and lung tumor. ME-344 can be used in the research of lung cancer, acute myeloid leukemia, and HER2-negative breast cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ME-344 | 99.80% | ME-344 is an Isoflavone. ME-344 increases mitochondrial ROS generation. ME-344 inhibits tubulin polymerization. ME-344 inhibits HO-1 and impacts its mitochondrial translocation. ME-344 induces Apoptosis through Caspase 3 activation. ME-344 synergizes with Vinblastine in leukemia cells. ME-344 displays anti-tumor activity against leukemia and lung tumor. ME-344 can be used in the research of lung cancer, acute myeloid leukemia, and HER2-negative breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang L, et al. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019;79(16):4072-4085. [Content Brief]
- [2]. Jeyaraju DV, et al. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. Oncotarget. 2016;7(31):49777-49785. [Content Brief]
- [3]. Quintela-Fandino M, et al. Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clin Cancer Res. 2020;26(1):35-45. [Content Brief]
- [4]. Hurrish K H, et al. A novel isoflavone, ME-344, enhances venetoclax antileukemic activity against AML via suppression of oxidative phosphorylation and purine biosynthesis[J]. Blood, 2021, 138: 2238.
